On the Interval-Based Dose-Finding Designs

The landscape of dose-finding designs for phase I clinical trials is rapidly shifting in the recent years, noticeably marked by the emergence of interval-based designs. We categorize them as the iDesigns and the IB-Designs. The iDesigns are originated by the toxicity probability inter- val (TPI) designs and its two modifications, the mTPI and mTPI-2 designs. The IB-Designs started as the cumulative cohort design (CCD) and is recently extended by the BOIN design. We discuss the differences and similarities between these two classes of interval-based designs, and compare their simulation performance with popular non-interval designs, such as the CRM and 3+3 designs. We also show that in addition to the population-level operating characteristics from simulated trials, investigators should also assess the dose-finding decision tables from the implemented designs to better understand the per-trial and per-patient behavior. This is particularly important for nonstatisticians to assess the designs with transparency. We pro- vide, to our knowledge, the most comprehensive simulation-based comparative study on various interval-based dose-finding designs.

[1]  Ying Yuan,et al.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.

[2]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[3]  Yuan Ji,et al.  A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. , 2016, Contemporary clinical trials.

[4]  Ying Yuan,et al.  Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[5]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[6]  Ying Kuen Cheung,et al.  Dose Finding by the Continual Reassessment Method , 2011 .

[7]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[8]  Yuan Ji,et al.  Dose-finding in phase I clinical trials based on toxicity probability intervals , 2007, Clinical trials.

[9]  Matthieu Clertant,et al.  Semiparametric dose finding methods , 2017 .

[10]  Nancy Flournoy,et al.  Cumulative cohort design for dose-finding , 2007 .

[11]  Xavier Paoletti,et al.  Design efficiency in dose finding studies , 2004, Comput. Stat. Data Anal..

[12]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[13]  Ying Kuen Cheung,et al.  A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.

[14]  J. Longmate,et al.  Toxicity equivalence range design (TEQR): a practical Phase I design. , 2011, Contemporary clinical trials.

[15]  H. Akaike A new look at the statistical model identification , 1974 .

[16]  James O. Berger,et al.  Ockham's Razor and Bayesian Analysis , 1992 .

[17]  Nancy Flournoy,et al.  Group up-and-down designs for dose-finding , 2006 .

[18]  Yuan Ji,et al.  An integrated dose-finding tool for phase I trials in oncology. , 2015, Contemporary clinical trials.

[19]  J. Berger Statistical Decision Theory and Bayesian Analysis , 1988 .

[20]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[21]  Yuan Ji,et al.  Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Yuan Ji,et al.  A modified toxicity probability interval method for dose-finding trials. , 2010, Clinical trials.

[23]  Yisheng Li,et al.  Bayesian dose finding in phase I clinical trials based on a new statistical framework , 2007 .

[24]  Nancy Flournoy,et al.  Dose Finding Using the Biased Coin Up‐and‐Down Design and Isotonic Regression , 2002, Biometrics.

[25]  H. Hatcher,et al.  25 – Clinical trials in cancer , 2011 .